Form 4: Haemonetics Director Robert Abernathy Receives RSU Grant

Haemonetics Corporation's Director, Robert E. Abernathy, was granted 2,693 restricted stock units as part of the company's long-term incentive plan.

Summary

• Robert E. Abernathy, a Director of Haemonetics Corp (HAE), was granted 2,693 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was July 24, 2025.
• These RSUs were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• The RSUs are scheduled to vest 100% on the first anniversary of the grant date.
• Following this transaction, Mr. Abernathy beneficially owns 24,981 shares of common stock.

Sentiment

Score: 7

Explanation: The filing reports a standard, expected compensation grant to a director, which aligns their interests with shareholders. This is generally viewed as a neutral to slightly positive event as it reinforces commitment without indicating any immediate financial distress or significant strategic shift.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction is part of a pre-existing, disclosed long-term incentive compensation plan, indicating a structured approach to executive and director compensation.

Future Outlook

The granted Restricted Stock Units (RSUs) are scheduled to vest 100% on the first anniversary of the grant date, which is July 24, 2026.

Industry Context

The grant of Restricted Stock Units (RSUs) to directors is a common practice across various industries, including the medical technology sector where Haemonetics operates, serving as a standard component of long-term incentive compensation to attract and retain talent and align interests with shareholders.

Comparison to Industry Standards

• Compensation in the form of Restricted Stock Units (RSUs) for directors is a widely adopted practice in publicly traded companies, including those in the medical device and healthcare technology sectors.
• While specific grant sizes vary based on company size, performance, and individual roles, the mechanism of using RSUs that vest over time is consistent with industry benchmarks for aligning director incentives with long-term shareholder value.
• For example, companies like Medtronic (MDT) or Abbott Laboratories (ABT) also utilize equity-based compensation plans for their non-employee directors, often including RSUs, to foster ownership and commitment.

Related Party Transactions

• The transaction involves the grant of Restricted Stock Units (RSUs) to Robert E. Abernathy, a Director of Haemonetics Corp, which constitutes a related party transaction as it is compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders by tying a portion of their compensation to the company's stock performance, potentially encouraging long-term value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units (RSUs) will vest 100% on the first anniversary of the grant date (July 24, 2026), at which point they will convert into shares of Haemonetics common stock.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction (an RSU grant to a director) that is part of a pre-existing compensation plan. Such a transaction is generally expected and does not provide new material information that would significantly alter the investment thesis for Haemonetics Corp. It reinforces alignment between management and shareholders but does not warrant a change in investment recommendation based solely on this filing.

Keywords

Haemonetics Corp, HAE, Robert E. Abernathy, Director, Restricted Stock Units, RSU, Stock Grant, Insider Transaction, Compensation Plan, SEC Form 4